JP Morgan Chase
OACC

JP Morgan Chase’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

JP Morgan Chase’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$528K Buy
49,930
+36
+0.1% +$383 ﹤0.01% 4957
2025
Q4 		$530K Sell
49,894
-24,923
-33% -$264K ﹤0.01% 4979
2025
Q3 		$783K Sell
74,817
-124,959
-63% -$1.31M ﹤0.01% 4755
2025
Q2 		$2.09M Buy
+199,776
New +$2.07M ﹤0.01% 3878

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $386M AUM 45.42% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.27B AUM 25.46% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BGIM
Boussard & Gavaudan Investment Management London, United Kingdom $1.06B AUM 4.58% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

JP Morgan Chase's OACC Position: Q1 2026 in Review

JP Morgan Chase increased its Oaktree Acquisition Corp III Life Sciences (OACC) stake by 0.07% in Q1 2026, buying an estimated $383 and bringing the position to 49,930 shares worth $528K. The position accounts for ﹤0.01% of the portfolio, ranked #4957.

JP Morgan Chase first reported a position in OACC in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.09M in Q2 2025. 51 funds tracked by Wall St. Rank hold OACC as of Q1 2026.

  • JP Morgan Chase held 49,930 shares of Oaktree Acquisition Corp III Life Sciences worth $528K as of Q1 2026.
  • JP Morgan Chase bought 36 Oaktree Acquisition Corp III Life Sciences shares in Q1 2026, an estimated $383.
  • Oaktree Acquisition Corp III Life Sciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4957 holding.
  • JP Morgan Chase first reported a position in Oaktree Acquisition Corp III Life Sciences in Q2 2025 and has held it in 4 quarters since.
  • JP Morgan Chase's Oaktree Acquisition Corp III Life Sciences position peaked at $2.09M in Q2 2025.
  • 51 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.